Skip to main content
Premium Trial:

Request an Annual Quote

GenapSys Raises $70M in Series D Financing

NEW YORK – Sequencing technology developer GenapSys said on Thursday that it has raised $70 million in Series D equity financing. The firm is also expanding its board of directors.

Farallon Capital Management and Soleus Capital led the round, joined by additional new investors who were not disclosed.

In a statement, GenapSys said it will use the proceed to further develop its semiconductor-based next-generation sequencing platform. CEO Jason Myers added that the firm would accelerate development of new products, particularly in oncology.

The Redwood City, California-based firm has now raised at least $236 million since 2013, plus $75 million in debt funding last year. The firm offers its benchtop GenapSys Sequencer and a library preparation instrument.

GenapSys is adding Bob Zollars, senior adviser at Frazier Healthcare Partners, and a representative of Farallon Capital to its board. Zollars was previously group president at Cardinal Health. He is also chair of the trustees of Arizona State University.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.